Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men

Finkelstein, Joel S.; Leder, Benjamin Z.; Burnett, Sherri-Ann M.; Wyland, Jason J.; Lee, Hang; Paz, Amanda Victoria de la; Gibson, Kate L.; Neer, Robert M.

doi:10.1210/jc.2006-0190

Cited by 130 publications

(66 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(21), the use of PTH in postmenopausal women revealed an increase in bone mass two times greater than in PTH combined with alendronate (21). However, another study has shown that alendronate enhances the effect of teriparatide on bone turnover in men (22).…”

Section: Discussionmentioning

confidence: 98%

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Sousa

Diniz

Marques

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the responses of serum β-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR). SUBJECTS AND METHODS: We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum β-CTX and osteocalcin levels were determined before and after the first and third months of teriparatide treatment and up to the fourth month of treatment with SR. RESULTS: We observed an initial significant increase in osteocalcin levels during the first month (165%, p = 0.01) followed by a peak of β-CTX (180%, p = 0.02) after the third month of treatment with teriparatide. An increase in these markers was also observed with SR: 49% in osteocalcin (p = 0.002) and 80% in β-CTX (p = 0.008). CONCLUSION: SR had a predominantly short-term bone-forming effect in postmenopausal women with osteoporosis previously treated with bisphosphonates in a lesser degree than with teriparatide.

show abstract

Section: Discussionmentioning

confidence: 98%

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Sousa

Diniz

Marques

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Changes in serum BTM were significantly greater in the teriparatide group than in the alendronate group or the combination therapy group (pb 0.001). As with BMD, a second study showed that alendronate impaired the action of teriparatide to increase bone turnover in men [79,80]. Previous studies in postmenopausal women also suggested that concomitant alendronate and PTH reduced the anabolic effects of PTH [75,81].…”

Section: Teriparatide Combination Therapymentioning

confidence: 95%

Treatment of osteoporosis in men

Ringe

2007

The Journal of Men's Health & Gender

View full text Add to dashboard Cite

Summary: Aspects of osteoporosis in men, such as screening and identification strategies, definitions of diagnosis and intervention thresholds, and treatment options (both approved and in the pipeline) are discussed. Introduction: Awareness of osteoporosis in men is improving, although it remains under-diagnosed and under-treated. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) workshop was convened to discuss osteoporosis in men and to provide a report by a panel of experts (the authors). Methods: A debate with an expert panel on preselected topics was conducted. Results and conclusions: Although additional fracture data are needed to endorse the clinical care of osteoporosis in men, consensus views were reached on diagnostic criteria and intervention thresholds. Empirical data in men display similarities with data acquired in women, despite pathophysiological differences, which may not be clinically relevant. Men should receive treatment at a similar 10-year fracture probability as in women. The design of mixed studies may reduce the lag between comparable treatments for osteoporosis in women becoming available in men.

show abstract

“…They are widely used clinically to treat diseases in which stability of bone mineral and bone quality are at risk 2 . Bisphosphonates have been shown to be effective in increasing bone mass in postmenopausal women [3][4][5] and osteoporotic men 6 , thereby preventing vertebral body and femoral neck fractures 7 . They are also successful therapeutics to treat osteolytic lesions induced by bone resorbing tumors 8 .…”

mentioning

confidence: 99%

Osteoinductivity of Demineralized Bone Matrix Is Independent of Donor Bisphosphonate Use

Schwartz

Hyzy

Moore

et al. 2011

The Journal of Bone and Joint Surgery-American Volume

View full text Add to dashboard Cite

Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men

Abstract: As with BMD, alendronate impairs the action of teriparatide to increase bone turnover in men.

Cited by 130 publications

References 32 publications

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Treatment of osteoporosis in men

Osteoinductivity of Demineralized Bone Matrix Is Independent of Donor Bisphosphonate Use

Contact Info

Product

Resources

About